This review summarizes the changes in the 5th Edition of the WHO Classification of
Endocrine and Neuroendocrine Tumors that relate to the pituitary gland. The new …

Substantial advances have been made recently in the pathobiology of pituitary tumors.
Similar to many other endocrine tumors, over the last few years we have recognized the role …

Objective Most pituitary tumours occur sporadically without a genetically identifiable
germline abnormality, a small but increasing proportion present with a genetic defect that …

Background: Acromegaly results from a persistent excess in growth hormone with clinical
features that may be subtle or severe. The most common cause of acromegaly is a pituitary …

Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

Growth hormone (GH)-secreting pituitary tumours represent the most genetically determined
pituitary tumour type. This is true both for germline and somatic mutations. Germline …

It is unclear how loss-of-function germline mutations in the widely-expressed co-chaperone
AIP, result in young-onset growth hormone secreting pituitary tumours. The RET receptor …

Brain tumors in children and adults are challenging tumors to treat. Malignant primary brain
tumors (MPBTs) such as glioblastoma have very poor outcomes, emphasizing the need to …

Pituitary adenomas are a common feature of a subset of endocrine neoplasia syndromes,
which have otherwise highly variable disease manifestations. We provide here a review of …

Introduction Somatostatin (SST) receptor ligands (SRL), in particular those of first generation
(Octreotide and Lanreotide), are widely used in medical treatment of acromegaly, but they …